Erastin and RSL3, which are known as ferroptosis activators, lead to the buildup of CHMP5 and CHMP6 in the plasma membrane of pancreatic cancer cells, and the knocking out of CHMP5 or CHMP6 intensifies the susceptibility of cancer cells to ferroptosis.146 Furthermore, in certain cases, FSP1 inhibits ferroptosis by promoting the accumulation of CHMP5 and CHMP6 on the plasma membrane.148 Overall, these findings highlight the critical role of ESCRT-III activation in preventing ferroptosis. This evidence concerns the gene CHMP6 and pancreatic neoplasm.